TFA Therapeutics, Inc. SEC filings RAJAF

TFA Therapeutics, Inc. has 38 filings in SEC EDGAR's recent list, going back to Dec 6, 2021. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 2, 2026. The company's fiscal year ends on December 31.

TFA Therapeutics, Inc. SEC filings
Form Description Filed Period
20-F Annual report (foreign issuer) May 15, 2026 Dec 31, 2025
20-F/A Amended annual report (foreign issuer) Sep 23, 2025 Dec 31, 2023
20-F Annual report (foreign issuer) Jun 13, 2025 Dec 31, 2024
20-F/A Amended annual report (foreign issuer) Oct 28, 2024 Dec 31, 2023
20-F Annual report (foreign issuer) Jul 5, 2024 Dec 31, 2023
20-F Annual report (foreign issuer) May 15, 2023 Dec 31, 2022

Showing 6 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as
RAJAF (OTC)
Fiscal year ends
December 31
Headquarters
Taipei City
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1885680
Former names
Cordyceps Sunshine Biotech Holdings Co., Ltd. (until Jun 25, 2026)

Other Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.